Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the market size for Hemophilia B gene therapy treatments with a focus on uniQure & Spark

Ticker(s): QURE, ONCE, PFE

Who's the expert?

Name: Dr Christopher Walsh - MD

Institution: Mount Sinai

  • Associate Professor & Director of the Hemophilia Program in the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, Regional Director of ATHN funded Hemophilia Treatment Centers in New England.
  • Currently manages 120 patients with Hemophilia B.
  • Research focuses on gene therapy of blood diseases. Pioneered the research into Adeno-Associated Virus (AAV) and its first use as a gene therapy vector; early work culminated in the first clinical trial in for gene therapy of patients with Fanconi Anemia Group C and Group A.

Interview Goal
To better understand the market size for gene therapy treatment of Hemophilia B including QURE's AMT-061 and ONCE's Fidanacogene elaparvovec (SPK-9001).

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.